4-Hydroxytamoxifen Inhibits Proliferation of Multiple Myeloma Cells In vitro through Down-Regulation of c-Myc, Up-Regulation of p27Kip1, and Modulation of Bcl-2 Family Members

Juliette Gauduchon (1) , Fabrice Gouilleux (2) , Sébastien Maillard , Véronique Marsaud (1) , Jack-Michel Renoir (3) , Brigitte Sola (4)

1 PCPB - Physico-chimie, pharmacotechnie, biopharmacie
2 GICC UMR 6239 CNRS - Génétique, immunothérapie, chimie et cancer (GICC), UMR 6239 CNRS [2008-2011]
3 UP11 - Université Paris-Sud - Paris 11
4 MILPAT - Microenvironnement cellulaire et pathologie

Cultured multiple myeloma cells were treated with various 4-OHT concentrations and the cellular response was studied: cell proliferation, cell viability, induction of apoptosis, caspase activities, and expression of signaling proteins.

Multiple myeloma is an incurable B-cell malignancy requiring new therapeutic strategies. Our approach was to analyze the in vitro effects of a selective estrogen receptor modulator, 4-hydroxytamoxifen (4-OHT), on six multiple myeloma cell lines.

Domains: Life Sciences [q-bio]; Life Sciences [q-bio]; Cancer

Juliette Gauduchon, Fabrice Gouilleux, Sébastien Maillard, Véronique Marsaud, Jack-Michel Renoir, et al.. 4-Hydroxytamoxifen Inhibits Proliferation of Multiple Myeloma Cells In vitro through Down-Regulation of c-Myc, Up-Regulation of p27Kip1, and Modulation of Bcl-2 Family Members. Clinical Cancer Research, 2005, 11 (6), pp.2345-2354. ⟨10.1158/1078-0432.CCR-04-1668⟩. ⟨hal-02427343⟩